SPRO (Spero Therapeutics) Valuation Rank


SPRO Spero Therapeutics Inc SPRO
55 GF Score
Price $2.02
GF Value $1.06
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Spero Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Spero Therapeutics Valuation Rank Related Terms

SPRO
55GF Score
Spero Therapeutics Inc SPRO
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Spero Therapeutics (SPRO) Overvalued in 2026?

Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued. The current stock price of $2.02 is trading 90.6% above its estimated GF Value™ of $1.06. GuruFocus considers Spero Therapeutics to be Significantly Overvalued.

Key valuation signals for SPRO:

  • Valuation Rank:
  • GF Value™: $1.06 vs. price of $2.02 (90.6% above fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Spero Therapeutics Business Description

Other Exchanges 2HA:Germany
Address 675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
55GF Score

Get the complete analysis for SPRO

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.02
Price
$1.06
GF Value